Ynsaurriaga Fernando Arribas, Peinado Rafael Peinado, Ormaetxe Merodio José Miguel
Servicio de Cardiología, Hospital 12 de Octubre, Madrid, Spain.
Future Cardiol. 2014 May;10(3):381-93. doi: 10.2217/fca.14.13.
Anticoagulation therapy is essential to reduce the risk of stroke in patients with atrial fibrillation. Traditionally, clinical trials have focused only on determining the efficacy and safety of anticoagulation but not on quality of life. In the last few years there has been a growing interest in determining the quality of life of patients treated with oral anticoagulation. In fact, specific tools that can evaluate quality of life related to atrial fibrillation and anticoagulation have been developed. Vitamin K antagonists have been shown to be effective in the prevention of thromboembolic complications. However, the use of vitamin K antagonists implies changes in behavior and lifestyle modifications that may have a negative impact on the quality of life. It has been suggested that self-monitoring of international normalized ratio could improve this impact. On the other hand, as new oral anticoagulants overcome these limitations, they may improve quality of life related with anticoagulant therapy. Unfortunately, although encouraging, the clinical experience with them is still quite limited.
抗凝治疗对于降低房颤患者的中风风险至关重要。传统上，临床试验仅专注于确定抗凝治疗的疗效和安全性，而未关注生活质量。在过去几年中，人们越来越关注接受口服抗凝治疗患者的生活质量。事实上，已经开发出了能够评估与房颤和抗凝治疗相关生活质量的特定工具。维生素K拮抗剂已被证明在预防血栓栓塞并发症方面有效。然而，使用维生素K拮抗剂意味着行为改变和生活方式调整，这可能会对生活质量产生负面影响。有人建议国际标准化比值的自我监测可以改善这种影响。另一方面，随着新型口服抗凝药克服了这些局限性，它们可能会改善与抗凝治疗相关的生活质量。不幸的是，尽管令人鼓舞，但关于它们的临床经验仍然相当有限。
